CIAS
ACAD icon

Capital Investment Advisory Services’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Investment Advisory Services’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-247
Closed -$9K – 554
2019
Q3 		$9K Hold
247
– – ﹤0.01% 998
2019
Q2 		$6K Hold
247
– – ﹤0.01% 1083
2019
Q1 		$7K Hold
247
– – ﹤0.01% 897
2018
Q4 		$4K Buy
+247
New +$4.8K ﹤0.01% 955

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Investment Advisory Services's ACAD Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Acadia Pharmaceuticals (ACAD) in Q4 2019, closing a stake of 247 shares — an estimated $9K sold.

Capital Investment Advisory Services first reported a position in ACAD in Q4 2018 and held it in 4 quarters. The position peaked at $9K in Q3 2019. 273 funds tracked by Wall St. Rank hold ACAD as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Acadia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 247 Acadia Pharmaceuticals shares in Q4 2019, an estimated $9K.
  • Capital Investment Advisory Services first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Capital Investment Advisory Services's Acadia Pharmaceuticals position peaked at $9K in Q3 2019.
  • 273 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.